Sur­prise flop for Cara’s oral pru­ri­tus drug forces com­pa­ny to cut its last R&D pro­gram

Cara Ther­a­peu­tics’ drug can­di­date has flopped in a mid-stage tri­al in peo­ple with mod­er­ate-to-se­vere itch due to a neu­ro­log­i­cal dis­or­der, prompt­ing the com­pa­ny to ter­mi­nate …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER